Vincritine, Dactinomycin and Cyclophosphomaide for Rhabdomyosarcoma (Sarcoma)

ID Number 80-0066-00052

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)


The purpose of this study is to see if lower doses of cyclophosphamide used together with current standard doses of vincristine and dactinomycin can be as effective or better in curing particpants as the standard doses of vincristine and dactinomycin. Another goal is to see if reduced doses of radiation therapy can be used for some patients and still be as effective in curing patients as standard doses of radiation therapy. The final goal is to see if the length of therapy can be shortened and still be effective in curing patients

Contact Information
Nita Narayan
(212) 241-4142

Recruiting Patients: No